Resverlogix Corp.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company's lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary sy… Read more
Resverlogix Corp. (RVXCF) - Total Assets
Latest total assets as of September 2025: $7.84 Million USD
Based on the latest financial reports, Resverlogix Corp. (RVXCF) holds total assets worth $7.84 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Resverlogix Corp. - Total Assets Trend (2001–2024)
This chart illustrates how Resverlogix Corp.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Resverlogix Corp. - Asset Composition Analysis
Current Asset Composition (December 2024)
Resverlogix Corp.'s total assets of $7.84 Million consist of 20.9% current assets and 79.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 1.4% |
| Accounts Receivable | $241.00K | 3.3% |
| Inventory | $996.00K | 13.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.49 Million | 33.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2001–2024)
This chart illustrates how Resverlogix Corp.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Resverlogix Corp.'s current assets represent 20.9% of total assets in 2024, a decrease from 62.4% in 2001.
- Cash Position: Cash and equivalents constituted 1.4% of total assets in 2024, down from 59.8% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 33.0% of total assets, an increase from 0.0% in 2001.
- Asset Diversification: The largest asset category is intangible assets at 33.9% of total assets.
Resverlogix Corp. Competitors by Total Assets
Key competitors of Resverlogix Corp. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Resverlogix Corp. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Resverlogix Corp. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Resverlogix Corp. is currently not profitable relative to its asset base.
Resverlogix Corp. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.04 | 0.08 | 0.11 |
| Quick Ratio | 0.02 | 0.04 | 0.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-40.01 Million | $ -22.93 Million | $ -9.88 Million |
Resverlogix Corp. - Advanced Valuation Insights
This section examines the relationship between Resverlogix Corp.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.83 |
| Asset Growth Rate (YoY) | 11.9% |
| Total Assets | $7.34 Million |
| Market Capitalization | $6.08 Million USD |
Valuation Analysis
Near Book Valuation: The market values Resverlogix Corp.'s assets close to their book value ( 0.83x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Resverlogix Corp.'s assets grew by 11.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Resverlogix Corp. (2001–2024)
The table below shows the annual total assets of Resverlogix Corp. from 2001 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $7.34 Million | +11.87% |
| 2023-12-31 | $6.57 Million | -19.10% |
| 2022-12-31 | $8.12 Million | -18.70% |
| 2021-12-31 | $9.98 Million | -12.27% |
| 2019-12-31 | $11.38 Million | -30.14% |
| 2018-12-31 | $16.29 Million | +96.75% |
| 2017-12-31 | $8.28 Million | -23.82% |
| 2016-12-31 | $10.87 Million | -72.90% |
| 2015-12-31 | $40.10 Million | +89.53% |
| 2014-12-31 | $21.16 Million | +599.14% |
| 2013-12-31 | $3.03 Million | -85.24% |
| 2012-12-31 | $20.50 Million | +65.68% |
| 2011-12-31 | $12.37 Million | +50.79% |
| 2010-12-31 | $8.20 Million | -2.72% |
| 2009-12-31 | $8.43 Million | -55.39% |
| 2008-12-31 | $18.91 Million | -8.71% |
| 2007-12-31 | $20.71 Million | +38.09% |
| 2006-12-31 | $15.00 Million | +86.05% |
| 2005-12-31 | $8.06 Million | -20.96% |
| 2004-12-31 | $10.20 Million | +278.45% |
| 2003-12-31 | $2.69 Million | +149.02% |
| 2002-12-31 | $1.08 Million | +199.12% |
| 2001-12-31 | $361.74K | -- |